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Summary:  
This review examines current knowledge about putative “pro-algesic” dietary 
components, and discusses whether limiting the intake of these substances can help 
improve chronic pain.  Although there is a common impression that numerous food 
components, natural and synthetic, can cause or worsen pain symptoms, very few of 
these substances have been investigated.  This article focuses on four substances, 
monosodium glutamate, aspartame, arachidonic acid, and caffeine, where research 
shows that overconsumption may induce or worsen pain.  For each substance, the 
mechanism whereby it may act to induce pain is examined, and any clinical trials 
examining the effectiveness of reducing the intake of the substance discussed.  While 
all four substances are associated with pain, decreased consumption of them does not 
consistently reduce pain. 
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Expert commentary:   
While an association between intake of certain dietary components and the 
exacerbation of pain conditions, such as headache, is not new, rigorous scientific 
investigation of these relationships is still limited.   Food additives are, understandably, 
subjected to a greater degree of investigation when they have been associated with the 
development of untoward effects such as pain.  Early investigations were often 
commercially motivated and as a result tended to minimize any association between 
pain symptoms and the food additive.   More recent examinations of food additives or 
dietary components with a suspected pain association identify monosodium glutamate 
(MSG) as having the strongest evidence for inducing or exacerbating existing pain, and 
aspartame as having the least.  However, large, well designed clinical trials of dietary 
reduction of MSG to manage chronic pain conditions remain to be conducted, so the 
employment of this strategy to treat pain is not yet supported by evidence.  On the other 
hand, as this type dietary modification has the potential to be pain reducing with few if 
any negative consequences, it will continue to be used by individuals who are looking 
for ways to treat their chronic pain.  It is important that health care professionals who 
treat persons with pain can discuss this approach to pain treatment.   
 
Five-year view:  
The development, in 2012, of a new, state-of-the-art National Institutes of Health 
research program focusing upon the role of the brain in perceiving, modifying, and 
managing pain at the National Center for Complementary and Integrative Health, whose 
mission is to fund and conduct research on complementary health approaches, 
demonstrates the very high level of public interest in alternative approaches to treating 
chronic pain.  The availability of increased funding in this area is likely to expand the 
number of studies on the utility of dietary modification in the treatment of pain over the 
next 5 years. 
 
Key issues:  
1. Monosodium glutamate is found in many foods, resulting in an average 
consumption of 170-250 mg/kg/day. 
2. Ingestion of a single dose of 150 mg/kg of MSG increases serum glutamate 
levels by up to 8 times normal and can result in reports of flushing, diffuse 
muscle aches, and headaches. 
3. Daily ingestion of 150 mg/kg MSG leads to increased reports of headache and 
muscle tenderness in young, healthy men and women. 
4. MSG sensitizes nociceptive nerve fibers and induces vasodilation of cranial 
blood vessels through activation of peripheral N-methyl-D-aspartate receptors. 
5. Elevated glutamate levels have been found in temporomandibular disorders and 
migraine headache, and reduction of dietary glutamate intake may reduce 
muscle pain symptoms in fibromyalgia. 
6. Daily consumption of aspartame is about 5 mg/kg, and at this level of intake, no 
association with pain conditions has been identified. 
7. Increased consumption of arachidonic acid has not yet been linked to increased 
pain reports, but, in theory this could elevate prostaglandin and leukotriene levels 
to promote inflammatory pain. 
8. Reduced intake of arachidonic acid and its precursor, linoleic acid, has been 
reported to reduce pain in rheumatoid arthritis and decrease the frequency of 
headaches in migraine. 
9. Increased daily caffeine intake (> 400 mg/day) has been associated with the 
development of headaches. 
10. Reduction of excessive caffeine intake has been shown to alleviate headache 
symptoms in some individuals, however, abrupt cessation of caffeine intake often 
causes headaches, which necessitates a slow taper of caffeine intake over 1-2 
weeks. 
 
 
 
  
Body of the Article: 
 
 Although strong associations have been made between the consumption of certain 
foods and chronic disease, notably cardiovascular disease, research that links diet to 
certain chronic pain conditions is still in its early stages.  It is known that some foods 
can trigger pain or aggravate existing pain conditions.  For example, consumption of 
gluten by individuals with gluten sensitivity can lead to gastrointestinal tract pain.   
Migraine headache is known to be triggered in some sufferers by specific foods like 
chocolate or wine [1-3].   However, less is known about the potential interaction 
between intake of specific dietary components and chronic pain conditions. Decreased 
intake of vitamins, for example B and D vitamin deficiencies, is associated with 
neuropathic pain conditions and muscle pain, respectively  [4].    Likewise, 
overconsumption of certain dietary components or food additives, such as 
polyunsaturated fatty acids and aspartame, has long been speculated to contribute to or 
even cause pain under certain conditions.  The concept that altered diet can be used to 
modify chronic diseases is also well accepted for conditions such as cardiovascular 
disease and diabetes.  Whether diets that limit the intake of dietary components or food 
additives are effective in modifying chronic pain remains a subject of ongoing research. 
The aim of this review is to shed light on what is known about putative “pro-algesic” 
dietary components, and to discuss whether limiting the intake of these substances can 
help improve certain pain conditions. 
 
 
 
Monosodium Glutamate (MSG) and Pain   
 MSG is a natural component of many foods, and is also added as a flavor 
enhancer.  Ingestion of large quantities of MSG is theorized to have a negative effect on 
pain in chronic pain patients [5].  Glutamate-rich foods include condensed soup, 
Parmesan cheese and packaged sauces, particularly tomato sauce, and seasonings [6].  
The median daily consumption of glutamate in the Western diet from all sources is 
around 12 g [7,8].  This is somewhere between 170 -250 mg/kg/day of glutamate.  A 
single fast food meal of a hamburger and milk shake contains approximately this 
amount of glutamate and has been shown to elevate serum glutamate concentrations 
for about 6 hours, with peak concentrations reaching ~250% of baseline concentrations 
by 2 hours after consumption [9]. This suggests that diets high in glutamate could result 
in a sustained elevation of glutamate concentrations.   
 
Association of MSG intake with pain. 
 Due to early reports of symptoms related to overconsumption of MSG, the acute 
effects of MSG administration have been fairly extensively examined.  Single oral doses 
of 150 mg/kg in adults have been reported to increase serum levels of glutamate 30 
minutes post ingestion by up to 800% [10].  A range of symptoms that include general 
weakness, muscle tightness, flushing/sweating, headache, paresthesias, arrhythmias 
and tachycardia have been reported after acute ingestion of MSG doses in this range 
[11-14].  Not all early studies conducted to investigate these MSG-induced effects 
consistently evoke these symptoms in healthy subjects, even if subjects reported they 
were “MSG sensitive” [7,14].  This led to suggestions that failure to adequately mask the 
unique taste of MSG may have been responsible for the high incidence of adverse 
effects reported by some researchers [7,14].  However, the development of MSG-
related symptoms has been found to be dose related, and oral administration of MSG 
results in highly variable serum glutamate concentrations [13], which may explain part of 
the variability in response to orally administered MSG.  Indeed, intravenous 
administration of 5 mg/kg glutamate still results in reports of burning sensations, facial 
pressure or chest tightness in association with peak serum levels of glutamate [12].  
Thus, the variability in symptoms reported after oral MSG ingestion most likely due to 
individual differences in the blood level of glutamate achieved after oral ingestion.   
 More recent studies support the concept that ingestion of large amounts of MSG can 
alter pain sensitivity in healthy, young men and women.  In a double-blinded, placebo-
controlled crossover study to investigate the effect of a single oral administration of 150 
mg/kg MSG, a significant correlation between plasma glutamate level and muscle pain 
tolerance in the temporalis muscles was found [15].   There was also a significant 
increase in reports of headache and pericranial muscle tenderness after MSG [15].    
Repeated administration of 150 mg/kg/day MSG for 5 days resulted in increased reports 
of headache and masseter muscle tenderness in healthy young adults [16].  
Interestingly, peak interstitial glutamate concentrations in the masseter muscle and 
plasma were increased after repeated ingestion of MSG over 5 days (Figure 1) [17].  
This result suggests that even short term increased intake of MSG results in tissue 
accumulation of glutamate, and that this may increase the risk of developing pain 
sensitivity.  
 
Why does MSG Alter Pain Sensitivity? 
How might ingestion of MSG lead to increased headaches and cranial muscle 
sensitivity?  Previous research indicates that doses of up to 1g/kg of MSG do not cross 
the blood-brain barrier [18,19], which suggests that observed effects of systemically 
administered MSG are mediated by peripheral rather than central mechanisms.  In rats, 
intravenously administered MSG (50 mg/kg) temporarily increases the interstitial 
concentration of glutamate in the masseter muscle from a baseline of 24 M to a peak 
concentration of 63 M [20].  This increase in glutamate concentration causes a 
decrease in the mechanical activation threshold and increase in the spontaneous action 
potential discharge of masseter muscle nociceptors [20].  The mechanical sensitization 
of masseter muscle nociceptors after intravenous MSG administration was attenuated 
by systemic administration of ketamine, a N-methyl-D-aspartate (NMDA) glutamate 
receptor subtype antagonist.  Intramuscular injection of glutamate into the masseter 
muscle has also been shown to evoke brief (< 10 min) nociceptor discharges as well as 
induce a prolonged period (> 3 hours) of mechanical sensitization in cranial muscle 
nociceptors that are also mediated through activation of peripheral NMDA receptors [21-
23].  Thus, the pain sensitizing effects of MSG appear to be mediated, in part, through 
activation of peripheral NMDA receptors expressed by a subgroup of masticatory 
muscle nociceptors [24-26].   
Elevated glutamate concentrations also promote vasodilation of cerebral blood 
vessels.  Glutamate-induced vasodilation is mediated through activation of NMDA 
receptors [21,27-30].  Glutamate-induced vasodilation appears to occur, in part, as a 
result of the release of the vasoactive neuropeptides calcitonin gene related peptide 
(CGRP) and substance P, and the production of nitric oxide [27,29] .  Thus, MSG-
induced headaches probably occur as a result of the combination of cerebral 
vasodilation and nociceptor sensitization.  
 
Can dietary restriction of MSG affect chronic pain conditions? 
 There is evidence that glutamate levels are elevated in migraine and tension type 
headache patients as well as in myofascial temporomandibular disorder patients.  
Multiple reports show that blood and salivary glutamate levels are elevated by 25-600% 
in migraine patients compared to healthy controls [31-35].  In addition, there is some 
evidence that glutamate levels in platelets are elevated in chronic tension-type 
headache sufferers [32].  Myofascial temporomandibular disorder (TMD) pain patients 
who report ongoing pain in their masseter muscle, have elevated interstitial 
concentrations of glutamate in this muscle compared to healthy controls [36]. These 
findings suggest that altered peripheral glutamate concentrations could be involved in 
the mechanism of generation of both migraine headache and myofascial pain. 
 Indirect evidence suggests that lowering blood glutamate concentration may be an 
important determinant of the effectiveness of migraine prophylactic therapy.  It has been 
found that mean baseline fasting plasma glutamate in 24 episodic migraine headache 
without aura patients was ~60 M as compared with ~ 10 M in 24 age and sex-
matched controls [35] .  Patients fasting plasma glutamate levels were reassessed 8 
weeks after initiation of a migraine prophylactic therapy (topiramate, propranolol, 
amitriptyline, or flunarizine).   Effective migraine prophylaxis was associated with a drop 
of glutamate from 60 M to 20 M.  Nevertheless, even after effective prophylaxis 
treatment, migraine headache patients still had blood glutamate concentrations that 
were twice those of healthy controls.   Whether a reduction in the consumption of MSG 
in migraine patients could also lead to decreased headache frequency has not been 
investigated. 
 The effectiveness of a reduction of dietary MSG intake and pain intensity has 
also been investigated in fibromyalgia patients, who suffer from chronic, widespread 
musculoskeletal pain.   A case report suggested that 4 women with fibromyalgia had 
significant improvement in their muscle pain after decreasing MSG from their diets, 
although it is unclear from this report what their consumption of MSG was before and 
after the implementation of this “MSG-free” diet [37].  A more recent study of 72 
fibromyalgia patients, which compared a restricted dietary intake of MSG and 
aspartame to no restriction in the diet, found no effect of reducing MSG intake on 
fibromyalgia pain [38].  However, it is unclear how effective the reduction of MSG intake 
was in this study, as data on MSG consumption at baseline and after the intervention 
were not reported.  In another study, 57 fibromyalgia patients with irritable bowel 
syndrome were put on a 4 week diet that restricted intake of MSG (and aspartame), 
and then, responders to the diet were re-challenged with MSG or placebo in a double 
blind, crossover study [39].  It was reported that more than 80% of patients reported a 
30% or better reduction in their pain on this diet.  Twenty six of the responders, who 
remained on the low MSG diet, then received either placebo or MSG (5 g, ~60 mg/kg) 
containing juice, for 3 days each week, for a total 2 weeks.   Visual analogue pain 
scores were 38% higher during the weeks when MSG was administered, compared 
with the weeks when placebo was administered.   The finding that pain in some 
fibromyalgia patients is affected by MSG consumption suggests that additional trials of 
low MSG diets are needed to determine whether this approach might be beneficial to 
treating pain and disability in this disorder. 
 
Aspartame and Pain 
 Aspartame (l-aspartate-l-phenylalanine-methyl ester) is an artificial sweetener 
~200 times sweeter than sugar [40].  It is estimated that daily aspartame intake in the 
US is about 5 mg/kg/day [40].   One of the most common complaints related to the 
ingestion of aspartame is the development of headache [41].  Aspartame is metabolized 
to aspartic acid, phenylalanine and methanol, with the aspartic acid usually considered 
the component most likely to potentially exacerbate pain [40]. 
 
Association of Aspartame with Pain  
Placebo controlled studies in healthy volunteers have not found a greater 
incidence of headache after aspartame consumption (25-30 mg/kg/day) than placebo 
[42,43].  In a double-blind crossover study, which used volunteers with self-identified 
aspartame headaches, it was reported that headaches occurred only slightly more 
often on 30 mg/kg aspartame for 7 days than on placebo [44].   The stronger subjects 
associated aspartame with their headaches, the more likely they were to report an 
increased frequency of headache.  However, in a small placebo controlled study in 
subjects who reported headache after ingestion of 150 mg/kg MSG but not placebo, 
oral administration of 34 mg/kg aspartame did not provoke headaches or other 
symptoms [45].  Plasma aspartate concentrations did not significantly change after 
administration of this dose of aspartame [45]. 
 
Why Might Aspartame Alter Pain Sensitivity? 
Aspartic acid is also a NMDA receptor agonist, and theoretically could act 
similarly to MSG, by activation of peripheral NMDA receptors.   It is unclear what 
increase in interstitial aspartate concentration would be necessary to sensitize 
nociceptors in deep tissues. 
 
Does dietary restriction of Aspartame alter chronic pain 
A trial of dietary restriction of aspartame and glutamate in fibromyalgia patients 
found no significant effect on pain [38].  Given that the only pain condition aspartame is 
associated with is headache, it seems unlikely that restriction of aspartame intake 
alone would have any effect on chronic, widespread pain. 
 
Arachidonic Acid and Pain 
The move to reduce omega 3 fatty acids in commercially prepared foods has led 
to an increase in omega 6 polyunsaturated fatty acids in the  modern diet [46].  
Arachidonic acid is an n-6 (omega 6) polyunsaturated fatty that is consumed in animal 
based foods such as eggs and meat [47].  As humans are unable to synthesize 
arachidonic acid de novo, it must either be consumed in the diet or synthesized from 
linoleic acid, an essential fatty acid, consumed in the diet [46,47].  As arachidonic acid 
is the precursor molecule for inflammatory and algogenic substances such as 
prostaglandins and leukotrienes, the effect of varying levels of this polyunsaturated 
fatty acid on pain is of significant interest. 
Association of arachidonic acid with pain 
Unlike glutamate and aspartame, increased consumption of arachidonic acid 
has not been associated with the development of pain conditions.  It is not clear if there 
is a certain level of consumption of linoleic acid or arachidonic acid that would lead to 
complaints of increased pain, or what types of pain this might affect.  It has been 
suggested that in certain neuropathic pain conditions like complex regional pain 
syndrome, patients appear to have an increased blood levels of metabolites of linoleic 
acid [47].  However, it is important to consider that linoleic acid is an essential dietary 
component, and if intake of this fatty acid is drastically reduced, effects on health, such 
as reproductive and immune dysfunction, occur [47].  Indeed, it is possible that certain 
pain conditions, such as diabetic neuropathy, could be made worse by reductions in the 
intake of linoleic or arachidonic acid, as diabetics have altered fatty acid metabolism. 
 
Why could an increase in arachidonic acid intake alter pain sensitivity? 
Cyclooxygenase and lipoxygenase act on arachidonic acid to produce 
prostaglandins and leukotrienes, respectively.  Elevation of prostaglandin E2 and 
leukotriene B4 in tissues decreases mechanical and thermal nociceptive thresholds in 
rats [48-50].  This could explain the association of elevated intake of arachidonic acid 
with altered pain sensitivity.  Indeed, subcutaneous injection of high concentrations of 
arachidonic acid ( ≥ 10 mM) induces edema and lowers nociceptive thresholds in rats 
[51,52].  Linoleic acid does not alter pain sensitivity when injected acutely.  However, it 
is not clear whether arachidonic acid has the same effect on pain if its intake is 
increased in the diet.   In a model of rheumatoid arthritis, which was initiated by 
subcutaneous injection of complete Freund’s adjuvant into the rat paw, rats fed an 
arachidonic acid rich diet had the expected elevated content of arachidonic acid in the 
paw skin [53].  However, there was no effect of this diet on arthritis-related increases in 
paw edema, or pathological joint changes such as bone erosion.  Further, although 
arthritis induction significantly increased prostaglandin E2, the concentration was not 
different in control animals and animals fed the elevated arachidonic acid containing 
diet.  Since prostaglandin E2 is one of the inflammatory mediators most associated with 
nociception, this suggests that the increased levels of arachidonic acid achievable by 
diet would not alter pain sensitivity, although additional research is needed to confirm 
this. 
It has also been reported that 2-20 M arachidonic acid can potentiate NMDA 
receptor currents in cultured neurons [54-56].  This effect happens too rapidly to be 
explained by conversion of arachidonic acid to a prostaglandin or leukotriene and does 
not alter currents in non-NMDA receptors, suggesting that it is due to a selective action 
on NMDA receptors.  As discussed above, peripheral NMDA receptors are expressed 
by nociceptors and their activation by MSG leads to reports of pain and sensitivity in 
humans.  Thus, it may be that arachidonic acid and MSG share a common mechanism 
for the induction of increased pain sensitivity. 
 
Can dietary restriction of arachidonic acid alter chronic pain? 
As humans cannot synthesize arachidonic acid de novo, it is feasible to reduce 
arachidonic acid levels through diets that restrict intake of linoleic acid, its precursor, 
and arachidonic acid [46].  Foods high in arachidonic acid include meats, dairy and 
eggs, so lowering of arachidonic acid intake may be accomplished by decreasing 
intake of these foods, e.g. a vegetarian diet. 
A pre-clinical study done in rats tested the effect of reducing linoleic acid from 
50% of to just 6.3% of the dietary intake of polyunsaturated fat on the development of 
signs of neuropathic pain produced by chronic constriction injury of the infraorbital 
nerve [57].  While the low linoleic acid diet slowed the development of mechanical 
sensitization, if did not prevent it from developing to a similar extent as animals who 
received a normal diet.  Thus, by 2 weeks post induction of the nerve injury, both 
groups of rats had a similar decrease in mechanical threshold over the face.  The low 
linoleic did, however, reduce plasma protein extravasation induced by capsaicin.  As 
capsaicin induced plasma protein extravasation is due, in part, to the release of 
inflammatory mediators, this suggests that the diet may have lowered inflammatory 
response.  Nevertheless, there was no long term benefit of the diet on the development 
of neuropathic-like pain in these animals. 
  Clinical trials in humans have been undertaken to examine the effectiveness of 
lowered arachidonic acid intake diets on arthritis and headache.  In a study of 
rheumatoid arthritis patients, it was reported that reduction of dietary intake of 
arachidonic acid by ⅔ of normal, lowered the number of painful joints by 14% [58].  A 
20% reduction of pain after 3 months of the low arachidonic acid diet was also reported, 
however, it is debatable whether this modest effect on pain is clinically meaningful.  
These improvements in pain were associated with a decrease in the level of leukotriene 
B4 in the blood [58].   As patients were allowed to remain on their drug therapy, which 
often included non-steroidal antiinflammatory drugs, there was little effect of the low 
arachidonic acid diet on prostaglandin E2 levels.   
 In patients with headache, there have been more mixed results associated with 
low arachidonic acid diets.  An earlier randomized, single-blinded, parallel-group study 
in  chronic daily headache (mostly migraine) sufferers, compared a diet of low 
arachidonic acid intake (50% reduction) to a diet of that consisted of low arachidonic 
acid with increased consumption of omega 3 fatty acids [58,59].   It was found that 
reduction of dietary intake of arachidonic acid alone reduced headache days from an 
average of 23 to 19, and headache duration by 1 hour per headache.  However, this 
study lacked a normal diet control group, so it is unclear how big the effect of simply 
being placed on a diet might have been, especially given the large placebo effect often 
seen in headache prophylaxis studies [59].  A more recent study using a similar low fat 
diet approach, failed to find any effect of the diet on the intensity, frequency or duration 
of migraine headaches [60].  At present, the effect of lowering arachidonic acid intake 
on migraine headache or rheumatoid arthritis pain appears modest, at best. 
Caffeine and Pain 
Caffeine is found in many foods and beverages consumed in the Western diet, 
most notably in coffee, with lesser amounts also found in soft drinks and chocolate.  A 
cup of brewed coffee contains between 60 and 135 mg or caffeine [61].   In North 
America and Northern Europe, average daily consumption of caffeine ranges from 200-
425 mg per day, with consumption in Scandinavia more than double consumption in the 
North America [61,62].  However, the current consensus is that intake of 200-400 mg of 
caffeine per day is not harmful to health and does not appear to increase pain 
complaints [61].  
Association of caffeine with pain  
Elevated daily consumption of caffeine (400–800 mg/day) is associated with 
increase anxiety, tachycardia, trembling and insomnia [63].  Some work suggests that 
consumption of more than 400 mg/day is a risk factor for the development of 
headaches [62,63].  Caffeine-related headaches are described as constant, dull, 
pressure like, and bilateral [61].  In a study of adult patients with chronic daily 
headache, it was reported that there appeared a higher daily consumption of caffeine 
prior to the onset of daily headaches, particularly in women with migraine headache 
[64].  However, daily caffeine intake was not predictive of headache in this study, and 
no cause-effect relationship between intake and headache could be established.  In 
some children and adolescents who report daily headaches, caffeine consumption of 
over 200mg/day (in the form of soft drinks) appears to be the cause, as headaches 
resolve if caffeine intake is lowered [61]. 
Why does caffeine alter pain sensitivity? 
Serum caffeine concentrations 1 hour after caffeine intake of 150 mg are around 
10-30 M [65].  Caffeine, in this concentration range, is a competitive antagonist at 
adenosine A1 and A2A receptors [63].  Antagonism of these receptors in the central 
nervous system by caffeine lengthens time to get to sleep (sleep latency), increases 
light over deep sleep and shortens total sleep time [63].  A polymorphism in the A2A 
receptor that alters its sensitivity to caffeine may explain some of the individual 
differences in sleep sensitivity [63].  As sleep deprivation is associated with increased 
pain sensitivity and headaches, this may provide one reason why elevated daily intake 
of caffeine might be associated with headache pain.  Another mechanism that may 
contribute to increased headaches is the ability of caffeine to reduce cerebral blood 
flow by competitive antagonism of the A2A receptor [65].  In a study of low (~45 
mg/day), moderate (~400 mg/day) and high (~ 900 mg/day) daily caffeine users, it was 
found that acute ingestion of caffeine reduced cerebral blood flow by about 20% [66].  
High daily caffeine users had lower cerebral blood flow than moderate or low daily 
users [65]. 
Caffeine also promotes calcium influx that would also be expected to promote 
contraction of smooth muscle, although at high concentrations (5-30 mM) outside of the 
concentration range normally obtained through oral consumption of caffeine containing 
foods and beverages.  However, recently it has been shown that 30 M caffeine 
inhibits the action of the excitatory amino acid transporter type 3 (EAAT3) glutamate 
transporter [67].  Glutamate transporters remove glutamate from the extracellular space 
and, in the central nervous system, the EAAT3 is found mainly on neurons.  Inhibition 
of glutamate reuptake by a caffeine mediated block, could lead to elevated levels of 
glutamate.  EAAT1-3 have been found to be expressed by trigeminal ganglion neurons 
and their associated satellite glial cells (Figure2) [68].  Indeed, inhibition of glutamate 
reuptake in the trigeminal ganglion leads to increased firing and mechanical 
sensitization of temporalis muscle nociceptors (Figure 3) [68].  As pain in the temporalis 
muscle is associated with headaches, the ability of caffeine to inhibit EAAT3 may also 
contribute to altered pain sensitivity and headache. 
Does dietary restriction of Caffeine alter chronic pain? 
It is recognized that abrupt cessation of caffeine intake in about half of regular 
consumers leads to a mild headache that is relieved by intake of caffeine [69-71].  
Withdrawal headaches are associated with an increase in cerebral blood flow [65]. 
However, tapered withdrawal of caffeine over a period of 1-2 weeks (depending on 
daily intake), prevents the development of this headache.  In children with caffeine 
associated headache, tapered withdrawal to no intake led to cessation of headache 
[61].  In a case report, reduction of caffeine intake from 360 mg/day to 2-10 mg/day 
resolved all pain symptoms in a 50 year old woman with trigeminal neuropathy, but no 
clinical study has ever been tried on this patient population [72].  In a single-blind, 
randomized clinical trial it was found that decreased consumption of caffeine did not 
decrease breast pain/tenderness in breast cancer sufferers [73].  Thus, at present, 
research suggests that caffeine withdrawal may be effective when caffeine is thought to 
be the cause of the pain condition, e.g. caffeine induced headache. 
 
Conclusions: 
 The concept that certain food components or food additives cause acute pain 
symptoms is not new, but has not been subjected to rigorous scientific investigation in 
many cases.  In some cases, such as MSG, a body of evidence does indicate that 
ingestion can lead to the development of specific pain complaints, however, it is not 
clear what the relationship of such findings are to the development and maintenance of 
chronic pain conditions.  Thus, whether excessive intake of certain dietary components 
contributes to chronic pain conditions remains an open question.   That being said, it is 
relatively easy to reduce consumption of caffeine, monosodium glutamate, aspartame 
and/or arachidonic acid in the diet, making this an attractive potential adjunctive 
treatment for certain patients with chronic pain conditions, in particular those with 
chronic headache or chronic musculoskeletal pain.  Given the growing recognition that 
treating chronic pain conditions with long term pharmacotherapy is problematic, 
alternative therapies that include diet modification are likely to continue growing in 
popularity.  
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*Cairns BE, Dong X, Mann MK et al. Systemic administration of monosodium glutamate 
elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent 
fibers. Pain, 132(1-2), 33-41 (2007). 
This is the first in vivo study demonstrating a relationship between glutamate 
concentrations and nociceptor sensitivity. 
**Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A. Effective prophylactic 
treatments of migraine lower plasma glutamate levels. Cephalalgia, 29(4), 423-429 
(2009). 
This study demonstrates that effective migraine prophylaxis is associated with a 
decrease in serum glutamate concentrations in migraineurs. 
**Holton KF, Taren DL, Thomson CA, Bennett RM, Jones KD. The effect of dietary 
glutamate on fibromyalgia and irritable bowel symptoms. Clin Exp Rheumatol, 30(6 
Suppl 74), 10-17 (2012). 
This very interesting study found that a subpopulation of fibromyalgia patients are MSG 
sensitive. 
*Magnuson BA, Burdock GA, Doull J et al. Aspartame: a safety evaluation based on 
current use levels, regulations, and toxicological and epidemiological studies. Crit Rev 
Toxicol, 37(8), 629-727 (2007) 
This article provides thorough review of the risks of aspartame intake. 
*Wagner K, Vito S, Inceoglu B, Hammock BD. The role of long chain fatty acids and 
their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat, 
113-115, 2-12 (2014) 
This comprehensive review examines the effects of polyunsaturated fatty acids on pain. 
*Nehlig A. Effects of coffee/caffeine on brain health and disease: What should I tell my 
patients? Pract Neurol,  (2015). 
This is a useful reference for health care providers who are asked about caffeine intake 
by their patients. 
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Figure Legends: 
 
Figure 1.  The line and scatter plots show the interstitial glutamate concentration in the 
masseter muscle measured by microdialysis before and after oral ingestion of 150 
mg/kg of MSG or sodium chloride (arrows) by healthy human subjects.  Subjects 
continued daily ingestion of MSG or sodium chloride (NaCl; 24 mg/kg) diluted with a 400 
ml soda daily for 5 days.  After 5 days, there was a significant increase in the peak 
interstitial concentration produced by ingestion of 150 mg/kg MSG.  There was a 
significantly higher frequency of reports of nausea and headache after ingestion of MSG 
and NaCl.  Adapted from [17]. 
 
Figure 2: The expression of excitatory amino acid transporter type 1 (EAAT1), EAAT2, 
and EAAT3 in the rat trigeminal ganglion is shown (green). Glutamine synthetase (GS) 
was used to identify satellite glial cells (red).  EAAT1 & EAAT2 were expressed by 
satellite glial cells (arrows). EAAT2 was also expressed in some neurons.  EAAT3 was 
predominantly expressed by neurons.   
 
Figure 3.  Microinjection of glutamate into the trigeminal ganglion results in action 
potential discharge and mechanical sensitization of muscle nociceptors in female rats 
(n=6 per group).  The graph in A shows the median discharge evoked by repeated 
injection of glutamate (Glu), compared to when the NMDA receptor antagonist APV, or 
the EATT antagonist TFB-TBOA were added to the second injection of glutamate.  
Repeated injection of glutamate resulted in relatively reproducible discharges that were 
attenuated by APV, and increased by TFB-TBOA.  The graph in B shows the 
mechanical threshold of afferent endings before (B) and after the same treaments. 
Repeated injections of glutamate significantly reduced the median mechanical 
threshold. Addition of APV attenuated this mechanical sensitization. Addition of TFB-
TBOA did not affect mechanical sensitization. Bars represent median cumulative 
discharge and lines indicate the interquartile range. *, p<0.05. 
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